EUVIMEDEUVIMED entdecken
Crossref

TARGETED PROTEIN DEGRADATION WITH PROTACS IN CANCER THERAPY: MECHANISMS, CLINICAL ADVANCES, CHALLENGES, AND FUTURE PERSPECTIVES

N. Vijaya Lakshmi Reddy, M. Sarika, V. Deepika, M. Hima Bindu, Syed Ahad Hussain

International Journal of Advanced Research · 31.07.2026 · 14 (07) · 919-942

DOI: 10.21474/ijar01/23847 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Advanced Research, online erschienen am 31.07.2026. Verfasst von N. Vijaya Lakshmi Reddy und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted protein degradation (TPD) has emerged as one of the most transformational approaches in current drug development, fundamentally challenging the long-standing assumption that small compounds must only inhibit their protein targets. Among TPD methods, proteolysis-targeting chimeras (PROTACs) have attracted considerable attention from both academic researchers and clinicians, giving a catalytic mechanism that permits the total removal of disease-driving proteins rather than just reducing their activity. This thorough analysis investigates the molecular basis of PROTAC technology, tracking its progression from an elegant intellectual notion to a clinically approved treatment platform. We discuss the molecular machinery of the ubiquitin - proteas ome system that PROTACs exploit, analyze the structural design principles underlying effective degrader molecules, and provide a detailed survey of the current clinical landscape,including the landmark progression of vepdegestrant (ARV-471) through Phase III clinical evaluation, culminating in U.S. Food and Drug Administration (FDA) approval on May 1, 2026.

Zitieren

APA

Reddy, N. V. L., Sarika, M., Deepika, V., Bindu, M. H., & Hussain, S. A. (2026). TARGETED PROTEIN DEGRADATION WITH PROTACS IN CANCER THERAPY: MECHANISMS, CLINICAL ADVANCES, CHALLENGES, AND FUTURE PERSPECTIVES. International Journal of Advanced Research, 14(07), 919-942. https://doi.org/10.21474/ijar01/23847

Vancouver

Reddy NVL, Sarika M, Deepika V, Bindu MH, Hussain SA. TARGETED PROTEIN DEGRADATION WITH PROTACS IN CANCER THERAPY: MECHANISMS, CLINICAL ADVANCES, CHALLENGES, AND FUTURE PERSPECTIVES. International Journal of Advanced Research. 2026;14(07):919-942. doi:10.21474/ijar01/23847

BibTeX
@article{Reddy2026,
  author = {Reddy, N. Vijaya Lakshmi and Sarika, M. and Deepika, V. and Bindu, M. Hima and Hussain, Syed Ahad},
  title = {TARGETED PROTEIN DEGRADATION WITH PROTACS IN CANCER THERAPY: MECHANISMS, CLINICAL ADVANCES, CHALLENGES, AND FUTURE PERSPECTIVES},
  journal = {International Journal of Advanced Research},
  year = {2026},
  volume = {14},
  number = {07},
  pages = {919--942},
  doi = {10.21474/ijar01/23847}
}
Kostenlos starten →